Mostrar el registro sencillo

dc.contributor.authorCoursier, Diane Léonie
dc.contributor.authorCalvo González, Fernando
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-05-15T14:15:39Z
dc.date.available2024-05-15T14:15:39Z
dc.date.issued2024
dc.identifier.issn2211-3428
dc.identifier.issn2211-3436
dc.identifier.otherMCIN/AEI/10.13039/501100011033es_ES
dc.identifier.urihttps://hdl.handle.net/10902/32845
dc.description.abstractNeoplastic progression involves complex interactions between cancer cells and the surrounding stromal milieu, fostering microenvironments that crucially drive tumor progression and dissemination. Of these stromal constituents, cancer-associated fibroblasts (CAFs) emerge as predominant inhabitants within the tumor microenvironment (TME), actively shaping multiple facets of tumorigenesis, including cancer cell proliferation, invasiveness, and immune evasion. Notably, CAFs also orchestrate the production of pro-angiogenic factors, fueling neovascularization to sustain the metabolic demands of proliferating cancer cells. Moreover, CAFs may also directly or indirectly affect endothelial cell behavior and vascular architecture, which may impact in tumor progression and responses to anti-cancer interventions. Conversely, tumor endothelial cells (TECs) exhibit a corrupted state that has been shown to affect cancer cell growth and inflammation. Both CAFs and TECs are emerging as pivotal regulators of the TME, engaging in multifaceted biological processes that significantly impact cancer progression, dissemination, and therapeutic responses. Yet, the intricate interplay between these stromal components and the orchestrated functions of each cell type remains incompletely elucidated. In this review, we summarize the current understanding of the dynamic interrelationships between CAFs and TECs, discussing the challenges and prospects for leveraging their interactions towards therapeutic advancements in cancer.es_ES
dc.description.sponsorshipFunding: Spanish Government MCIN/AEI/10.13039/501100011033 (grants RYC-2016‐20352, RTI2018‐096778‐A‐I00, PID2021‐ 128107OB‐I00); Asociación Española Contra el Cáncer-AECC (grants LABAE19044CALV, PRYCO211372RODR); BBVA Leonardo Awards (grant IN [19]_BBM_BAS_0076), Cancer Research UK (grant C57744/A22057); and the European Research Council-ERC Consolidator Grant antiCAFing (grant ref 101045756). Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Acknowledgements: The authors would like to thank all members of the FC laboratory for help, support and discussions associated with this manuscript. We also thank Emad Moeendarbary and his lab members (UCL, London, UK) for key contributions in current CAF-TEC projects within FC laboratory. We are grateful for financial support by Spanish Government MICIU/AEI/10.13039/501100011033 (grants RYC‐2016‐20352, RTI2018‐096778‐A‐I00, PID2021‐128107OB‐ I00); Asociación Española Contra el Cáncer-AECC (grants LABAE-19044CALV, PRYCO211372RODR); BBVA Leonardo Awards (grant IN[19]_BBM_BAS_0076), Cancer Research UK (grant C57744/ A22057); and the European Research Council-ERC Consolidator Grant antiCAFing (grant 101045756). DC has been a recipient of a Boehringer Ingelheim Fonds PhD Travel Grant. Finally, we would like to dedicate this work to the memory of David Alburquerque Gutiérrez. He was a great friend whose humanity will continue to inspire us.es_ES
dc.format.extent22 p.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.rights© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceCellular Oncology, 2024es_ES
dc.subject.otherCanceres_ES
dc.subject.otherTumor microenvironmentes_ES
dc.subject.otherEndotheliaes_ES
dc.subject.otherCAFses_ES
dc.subject.otherSignalinges_ES
dc.subject.otherCrosstalkes_ES
dc.titleCAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistancees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1007/s13402-024-00931-z
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.Excepto si se señala otra cosa, la licencia del ítem se describe como © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.